Insights

  • Date

  • Content Type

  • Reset

Blog

With ATMP innovation on the rise, sponsors see increase in FDA IND holds

18.04.23

By By Dr. Paula Vaccarello and Dr. Jörg Schneider

With more innovator companies targeting cell and gene therapy, it’s not surprising that investigational new
Read More

Article

Paving the Way for Cancer Vaccine Success

7.04.23

By Drs Daina Vanags, Cori Gorman and Christian K. Schneider

Breakthroughs with immunotherapy and the mRNA platform are heralding a new dawn for cancer treatment.
Read More

Blog

Understanding diverging expectations between FDA and EMA with cell and gene therapy

4.04.23

By Cori Gorman, Ph.D.

Successfully bringing cell and gene therapies through the regulatory process requires preparation and knowing what
Read More

Blog

Planning for CBER and EMA success with cell and gene therapy

28.03.23

By Cori Gorman, Ph.D.

The fields of cell and gene therapy are enormously promising while at the same time
Read More

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more